By Conjoint Professor David goldstein

Journal articles

Janda M; Neale RE; Klein K; O'Connell DL; Gooden H; Goldstein D; Merrett ND; Wyld DK; Rowlands IJ; Beesley VL, 2017, 'Anxiety, depression and quality of life in people with pancreatic cancer and their carers', Pancreatology, 17, pp. 321 - 327, http://dx.doi.org/10.1016/j.pan.2017.01.008

Lees JG; Makker PGS; Tonkin RS; Abdulla M; Park SB; Goldstein D; Moalem-Taylor G, 2017, 'Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy', European Journal of Cancer, 73, pp. 22 - 29, http://dx.doi.org/10.1016/j.ejca.2016.12.006

Goldstein D; Lemech C; Valle J, 2017, 'New molecular and immunotherapeutic approaches in biliary cancer', ESMO Open, 2, pp. e000152, http://dx.doi.org/10.1136/esmoopen-2016-000152

Watts KJ; Meiser B; Zilliacus E; Kaur R; Taouk M; Girgis A; Butow P; Goldstein D; Hale S; Perry A; Aranda SK; Kissane DW, 2017, 'Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals', European Journal of Oncology Nursing, 26, pp. 83 - 90, http://dx.doi.org/10.1016/j.ejon.2016.12.001

Tang M; Chen J; Goldstein D; Links M; Lord S; Marschner I; Simes J; Lee CK, 2017, 'Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).', JOURNAL OF CLINICAL ONCOLOGY, 35, http://dx.doi.org/10.1200/JCO.2017.35.4_suppl.227

Chan DL; Sjoquist KM; Goldstein D; Price TJ; Martin AJ; Bang YJ; Kang YK; Pavlakis N, 2017, 'The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis', Plos One, 12, pp. e0172307, http://dx.doi.org/10.1371/journal.pone.0172307

Makker PGS; Duffy SS; Lees JG; Perera CJ; Tonkin RS; Butovsky O; Park SB; Goldstein D; Moalem-Taylor G, 2017, 'Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy', Plos One, 12, pp. e0170814, http://dx.doi.org/10.1371/journal.pone.0170814

Sharbeen G; Youkhana J; Mawson A; McCarroll J; Nunez A; Biankin A; Johns A; Goldstein D; Phillips P, 2017, 'MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity', Oncotarget, 8, pp. 9216 - 9229, http://dx.doi.org/10.18632/oncotarget.13985

Ritchie GE; Fernando M; Goldstein D, 2017, 'Rituximab to treat gemcitabine-induced hemolytic–uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review', Cancer Chemotherapy and Pharmacology, 79, http://dx.doi.org/10.1007/s00280-016-3123-6

Pothula SP; Xu Z; Goldstein D; Merrett N; Pirola RC; Wilson JS; Apte MV, 2017, 'Targeting the HGF/c-MET pathway: Stromal remodelling in pancreatic cancer', Oncotarget, 8, pp. 76722 - 76739, http://dx.doi.org/10.18632/oncotarget.20822

Tang M; Goldstein D, 2017, 'The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia', Journal of Gastrointestinal Oncology, 8, pp. E10 - E15, http://dx.doi.org/10.21037/jgo.2016.11.14

Kunzmann V; Ramanathan RK; Goldstein D; Liu H; Ferrara S; Lu B; Renschler MF; Von Hoff DD, 2017, 'Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study', Pancreas, 46, pp. 203 - 208, http://dx.doi.org/10.1097/MPA.0000000000000742

Schernberg A; Vernerey D; Goldstein D; Van Laethem JL; Van Houtte PJ; Bonnetain F; Glimelius B; Louvet C; Hammel P; Huguet F, 2017, 'Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial', International Journal of Radiation Oncology*Biology*Physics, 99, pp. S88 - S89, http://dx.doi.org/10.1016/j.ijrobp.2017.06.213

Burmeister EA; O’Connell DL; Jordan SJ; Goldstein D; Merrett N; Wyld DK; Beesley VL; Gooden HM; Janda M; Neale RE, 2016, 'Factors associated with quality of care for patients with pancreatic cancer in Australia', Medical Journal of Australia, 205, pp. 459 - 465, http://dx.doi.org/10.5694/mja16.00567

Yang JL; Lim HJ; Wang X; Crowe PJ; Goldstein D, 2016, 'Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines', Anticancer research, 36, pp. 5765 - 5772, http://dx.doi.org/10.21873/anticanres.11160

Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA; goldstein D, 2016, 'Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge', Cancer Treatment Reviews, 50, pp. 118 - 128, http://dx.doi.org/10.1016/j.ctrv.2016.09.005

Vickers MM; Lee C; Tu D; Wheatley-Price P; Parulekar W; Brundage MD; Moore MJ; Au H; O'Callaghan CJ; Jonker DJ; Ringash J; Goldstein D, 2016, 'Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3', Pancreatology, 16, pp. 1106 - 1112, http://dx.doi.org/10.1016/j.pan.2016.08.013

Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D, 2016, 'Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer (vol 115, pg 188, 2016)', BRITISH JOURNAL OF CANCER, 115, pp. E13 - U13, http://dx.doi.org/10.1038/bjc.2016.306

Huguet F; Goldstein D; Hammel P, 2016, 'Radiation therapy deviations in trial of locally advanced pancreatic cancer: In Reply', JAMA Journal of the American Medical Association, 316, pp. 1409 - 1410, http://dx.doi.org/10.1001/jama.2016.9781

de Souza P; Chua W; Clarke S; Goldstein D; Lee C, 2016, 'Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis', European Urology Focus, 2, pp. 341 - 342, http://dx.doi.org/10.1016/j.euf.2016.04.007

Gormly KL; Coscia C; Wells T; Tebbutt N; Harvey JA; Wilson K; Schmoll HJ; Price T; Hruby G; Jeffery M; Karapetis C; Ng W; Singhal N; Burge M; Lynch R; Briscoe K; Begbie S; Gill S; Sebesan S; Goldstein D; Ng S; Asghari R; Blum R; Walpole E; Byard I, 2016, 'MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial', Journal of Medical Imaging and Radiation Oncology, 60, pp. 607 - 615, http://dx.doi.org/10.1111/1754-9485.12493

Wang X; Goldstein D; Crowe PJ; Yang JL, 2016, 'Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: A review of the evidence', Oncotargets and Therapy, 9, pp. 5461 - 5473, http://dx.doi.org/10.2147/OTT.S94745

Burmeister EA; Waterhouse M; Jordan SJ; O'Connell DL; Merrett ND; Goldstein D; Wyld D; Beesley V; Gooden H; Janda M; Neale RE, 2016, 'Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study', Pancreatology, 16, pp. 873 - 881, http://dx.doi.org/10.1016/j.pan.2016.06.010

Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D, 2016, 'Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial', Journal of Clinical Oncology, 34, pp. 2728 - 2735, http://dx.doi.org/10.1200/JCO.2015.65.1901

Waterhouse MA; Burmeister EA; O’Connell DL; Ballard EL; Jordan SJ; Merrett ND; Goldstein D; Wyld D; Janda M; Beesley VL; Payne ME; Gooden HM; Neale RE, 2016, 'Determinants of Outcomes Following Resection for Pancreatic Cancer—a Population-Based Study', Journal of Gastrointestinal Surgery, 20, pp. 1471 - 1481, http://dx.doi.org/10.1007/s11605-016-3157-4

Beesley V; Wockner L; O'Rourke P; Janda M; Merrett H; Goldstein D; Gooden H; Merrett N; O'Connell D; Rowlands I; Wyld D; Neale R, 2016, 'Erratum to: Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study (Support Care Cancer, 10.1007/s00520-016-3212-4)', Supportive Care in Cancer, 24, pp. 3601 - 3602, http://dx.doi.org/10.1007/s00520-016-3251-x

Beesley VL; Wockner LF; O’Rourke P; Janda M; Goldstein D; Gooden H; Merrett ND; O’Connell DL; Rowlands IJ; Wyld DK; Neale RE, 2016, 'Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study', Supportive Care in Cancer, 24, pp. 3589 - 3599, http://dx.doi.org/10.1007/s00520-016-3212-4

Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J; Do V; Marschner I; Friedlander M; Gurney H; Simes J; Hague W; O’Connell R; Gorzeman M; Pike R; Miranda K; Waring P; Lau D; Fox S; Liu Y; Wood T; Cocks C; Simmons K; McCourt J; Jefford M; Hobinchet A; Mirco B; Sagong J; Dudukovic S; Aghmesheh M; Parker S; Segelov E; Ratnayake L; Ranieri N; Varma S; Page J; Heyer E; Abdi E; Chorlton C; Wilkinson L; Marshall I, 2016, 'TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer', Cancer Chemotherapy and Pharmacology, 78, pp. 361 - 367, http://dx.doi.org/10.1007/s00280-016-3089-4

Vernerey D; Huguet F; Vienot A; Goldstein D; Paget-Bailly S; Van Laethem JL; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Benetkiewicz M; Louvet C; Hammel P; Bonnetain F, 2016, 'Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)', British Journal of Cancer, 115, pp. 281 - 289, http://dx.doi.org/10.1038/bjc.2016.212

Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D, 2016, 'Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer', British Journal of Cancer, 115, pp. 188 - 194, http://dx.doi.org/10.1038/bjc.2016.185

Gandy RC; Barbour AP; Samra J; Nikfarjam M; Haghighi K; Kench JG; Saxena P; Goldstein D, 2016, 'Refining the care of patients with pancreatic cancer: The AGITG Pancreatic Cancer Workshop consensus', Medical Journal of Australia, 204, pp. 419 - 422.e1, http://dx.doi.org/10.5694/mja16.00061

Gandy RC; Barbour AP; Samra J; Nikfarjam M; Haghighi K; Kench JG; Saxena P; Goldstein D, 2016, 'Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus', MEDICAL JOURNAL OF AUSTRALIA, 204, pp. 419 - +, http://dx.doi.org/10.5694/mja16.00061

Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD, 2016, 'Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial', Journal of Gastrointestinal Oncology, 7, pp. 469 - 478, http://dx.doi.org/10.21037/jgo.2016.01.03

Shaw JM; Shepherd HL; Durcinoska I; Butow PN; Liauw W; Goldstein D; Young JM, 2016, 'It’s all good on the surface: care coordination experiences of migrant cancer patients in Australia', Supportive Care in Cancer, 24, pp. 2403 - 2410, http://dx.doi.org/10.1007/s00520-015-3043-8

Burmeister EA; Jordan SJ; O’Connell DL; Beesley VL; Goldstein D; Gooden HM; Janda M; Merrett ND; Wyld D; Neale RE; Cosman PH; Bullen A; Burge M; Eastgate M; Powell J; Deuble M; Pryor D; Whelan J; Algie L; Gupta S; Lynch SV; Burmeister BH; Slater K; Fletcher D; Van Hazel G; Raftopoulos S; Spry N; Agar M; Brecciaroli F; Caird S; Cameron D; Chan P; Chantrill L; Christie D; Chua YJ; Croese J; Cronk M; Gani J; Grimison P; Hruby G; Jefford M; Samra JS; Wysocki AP, 2016, 'Using a Delphi process to determine optimal care for patients with pancreatic cancer', Asia Pacific Journal of Clinical Oncology, 12, pp. 105 - 114, http://dx.doi.org/10.1111/ajco.12450

Barbour A; O'Rourke N; Chan H; Chua YJ; Kench J; Hicks RJ; Samra JS; Pavlakis N; Haghighi KS; Yip S; Donoghoe M; Friend C; Burge ME; Fawcett J; Harris M; Aghmesheh M; Joubert WL; Gebski V; Simes J; Goldstein D, 2016, 'Initial survival outcomes for the AGITG GAP study - a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC)', JOURNAL OF CLINICAL ONCOLOGY, 34, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.4105

Hammel P; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C, 2016, 'Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial', JAMA Journal of the American Medical Association, 315, pp. 1844 - 1853, http://dx.doi.org/10.1001/jama.2016.4324

Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A, 2016, 'CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer', Annals of Oncology, 27, pp. 654 - 660, http://dx.doi.org/10.1093/annonc/mdw006

Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD, 2016, 'Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas', Annals of Oncology, 27, pp. 648 - 653, http://dx.doi.org/10.1093/annonc/mdw020

He EYJ; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL, 2016, 'The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: An Australian population-based multicenter study', Oncologist, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530

Chantrill L; Goldstein D, 2016, 'Pancreatic cancer', Cancer Forum, 40, pp. 3 - 5

McLachlan SA; Fisher RJ; Zalcberg J; Solomon M; Burmeister B; Goldstein D; Leong T; Ackland SP; McKendrick J; McClure B; MacKay J; Ngan SY, 2016, 'The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)', European Journal of Cancer, 55, pp. 15 - 26, http://dx.doi.org/10.1016/j.ejca.2015.10.060

Wang X; Goldstein D; Crowe P; Yang M; Garrett K; Zeps N; Yang JL, 2016, 'Overcoming resistance of targeted egfr monotherapy by inhibition of stat3 escape pathway in soft tisue sarcoma', Oncotarget, 7, pp. 21496 - 21509, http://dx.doi.org/10.18632/oncotarget.7452

Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV, 2016, 'Hepatocyte growth factor inhibition: A novel therapeutic approach in pancreatic cancer', British Journal of Cancer, 114, pp. 269 - 280, http://dx.doi.org/10.1038/bjc.2015.478

Goldstein D; Chiorean EG; Tabernero J; El-Maraghi RH; Ma WW; Reni M; Harris M; Whorf RC; Coughlin S; Li J; Manax VG; Lu BD; Romano A; Von Hoff DD, 2016, 'Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 34, pp. 333 - 333, http://dx.doi.org/10.1200/jco.2016.34.4_suppl.333

Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC, 2016, 'Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial', BMC Cancer, 16, pp. 22, http://dx.doi.org/10.1186/s12885-016-2051-5

O’Callaghan C; Schofield P; Butow P; Nolte L; Price M; Tsintziras S; Sze M; Thein T; Yiu D; Mireskandari S; Goldstein D; Jefford M, 2016, '“I might not have cancer if you didn’t mention it”: a qualitative study on information needed by culturally diverse cancer survivors', Supportive Care in Cancer, 24, pp. 409 - 418, http://dx.doi.org/10.1007/s00520-015-2811-9

Sharbeen G; McCarroll J; Liu J; Youkhana J; Limbri LF; Biankin AV; Johns A; Kavallaris M; Goldstein D; Phillips PA, 2016, 'Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids', Neoplasia United States, 18, pp. 753 - 764, http://dx.doi.org/10.1016/j.neo.2016.10.011

Goldstein D; Von Hoff DD; Moore M; Greeno E; Tortora G; Ramanathan RK; Macarulla T; Liu H; Pilot R; Ferrara S; Lu B, 2016, 'Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)', European Journal of Cancer, 52, pp. 85 - 91, http://dx.doi.org/10.1016/j.ejca.2015.10.017

Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L, 2016, 'Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?', European Journal of Cancer, 53, pp. 96 - 104, http://dx.doi.org/10.1016/j.ejca.2015.10.006

Back to profile page